ATE411041T1 - Verwendung von fviia oder eines gewebefaktoragonisten zur regulierung der genexpression und zellmigration oder chemotaxis - Google Patents
Verwendung von fviia oder eines gewebefaktoragonisten zur regulierung der genexpression und zellmigration oder chemotaxisInfo
- Publication number
- ATE411041T1 ATE411041T1 AT00943706T AT00943706T ATE411041T1 AT E411041 T1 ATE411041 T1 AT E411041T1 AT 00943706 T AT00943706 T AT 00943706T AT 00943706 T AT00943706 T AT 00943706T AT E411041 T1 ATE411041 T1 AT E411041T1
- Authority
- AT
- Austria
- Prior art keywords
- cell migration
- fviia
- chemotaxis
- gene expression
- tissue factor
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000012292 cell migration Effects 0.000 title abstract 2
- 102000002262 Thromboplastin Human genes 0.000 title 1
- 108010000499 Thromboplastin Proteins 0.000 title 1
- 230000034196 cell chemotaxis Effects 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000012760 regulation of cell migration Effects 0.000 abstract 1
- 230000015167 regulation of chemotaxis Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901023 | 1999-07-14 | ||
| US14830099P | 1999-08-11 | 1999-08-11 | |
| DKPA199901117 | 1999-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411041T1 true ATE411041T1 (de) | 2008-10-15 |
Family
ID=27221063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00943706T ATE411041T1 (de) | 1999-07-14 | 2000-07-14 | Verwendung von fviia oder eines gewebefaktoragonisten zur regulierung der genexpression und zellmigration oder chemotaxis |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20020193302A1 (de) |
| EP (1) | EP1200116B1 (de) |
| JP (1) | JP2003525028A (de) |
| KR (1) | KR100821644B1 (de) |
| CN (1) | CN100411684C (de) |
| AT (1) | ATE411041T1 (de) |
| AU (1) | AU5807500A (de) |
| BR (1) | BR0012408A (de) |
| CA (1) | CA2378249A1 (de) |
| CZ (1) | CZ200240A3 (de) |
| DE (1) | DE60040539D1 (de) |
| ES (1) | ES2316372T3 (de) |
| HU (1) | HUP0302052A3 (de) |
| IL (1) | IL147294A0 (de) |
| MX (1) | MXPA02000468A (de) |
| NO (1) | NO20020130L (de) |
| PL (1) | PL353035A1 (de) |
| RU (1) | RU2268744C2 (de) |
| WO (1) | WO2001005353A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271365A1 (en) * | 2000-06-21 | 2002-01-02 | Wyeth | Cyr61 as a target for treatment and diagnosis of breast cancer |
| DE10238429A1 (de) | 2002-03-19 | 2003-10-30 | Aventis Behring Gmbh Intellect | Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose |
| US6858587B2 (en) | 2001-11-02 | 2005-02-22 | Novo Nordisk Pharmaceuticals, Inc. | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| EP1443956A2 (de) * | 2001-11-02 | 2004-08-11 | Novo Nordisk Health Care AG | Verwendung des gewebefaktor-agonisten oder gewebefaktor-antagonisten zur behandlung von erkrankungen im zusammenhang mit apoptose |
| EP1471818A4 (de) * | 2002-02-04 | 2007-03-28 | Millennium Pharm Inc | Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen unter verwendung von 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 oder 13249 molekülen |
| CA2534996A1 (en) * | 2003-08-06 | 2005-05-06 | Hans Prydz | The use of sirna silencing in the prevention of metastasis |
| KR20070012715A (ko) * | 2004-04-16 | 2007-01-26 | 더 스크립스 리서치 인스티튜트 | 혈관신생 조절방법 |
| US20100028358A1 (en) * | 2005-11-07 | 2010-02-04 | Wolfram Ruf | Compositions and Methods for Controlling Tissue Factor Signaling Specificity |
| WO2008103812A1 (en) * | 2007-02-21 | 2008-08-28 | Yale University | Compositions and methods for diagnosing and treating endometriosis |
| JP5905258B2 (ja) | 2011-07-01 | 2016-04-20 | 株式会社 資生堂 | 血小板由来成長因子−bb産生亢進剤、並びにそれを含む間葉系幹細胞産生促進剤、幹細胞安定化剤、及び真皮再生化剤 |
| CN109381478A (zh) * | 2018-10-31 | 2019-02-26 | 青岛大学附属医院 | 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123338C1 (ru) * | 1990-06-15 | 1998-12-20 | Сайтел Корпорейшн | Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения |
| AU2793292A (en) * | 1991-10-11 | 1993-05-03 | Novo Nordisk A/S | Hemostatic composition for local hemostasis |
| DE19538715A1 (de) * | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| JP4307552B2 (ja) * | 1996-03-15 | 2009-08-05 | ミューニン コーポレイション | 細胞外マトリックスシグナリング分子 |
| WO1998058661A1 (en) | 1997-06-23 | 1998-12-30 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
| US20030040481A1 (en) * | 1997-07-18 | 2003-02-27 | Lars Kongsbak | Methods for modifying cell motility using a factor VIIa antagonist |
| ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
| AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| ES2432967T3 (es) | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
| IL158615A0 (en) | 2001-05-02 | 2004-05-12 | Novo Nordisk As | Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome |
| IL159622A0 (en) | 2001-07-20 | 2004-06-01 | Novo Nordisk Healthcare Ag | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| EP1446155A1 (de) | 2001-11-09 | 2004-08-18 | Novo Nordisk A/S | Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und aprotinin-polypeptiden |
| JP2006510568A (ja) | 2001-11-09 | 2006-03-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物 |
| EP1446147A1 (de) | 2001-11-09 | 2004-08-18 | Novo Nordisk Health Care AG | Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält |
| JP2005511599A (ja) | 2001-11-09 | 2005-04-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチド及びv因子ポリペプチドを含む薬学的組成物 |
-
2000
- 2000-07-14 KR KR1020027000527A patent/KR100821644B1/ko not_active Expired - Fee Related
- 2000-07-14 AU AU58075/00A patent/AU5807500A/en not_active Abandoned
- 2000-07-14 EP EP00943706A patent/EP1200116B1/de not_active Expired - Lifetime
- 2000-07-14 IL IL14729400A patent/IL147294A0/xx unknown
- 2000-07-14 DE DE60040539T patent/DE60040539D1/de not_active Expired - Lifetime
- 2000-07-14 RU RU2002103602/15A patent/RU2268744C2/ru not_active IP Right Cessation
- 2000-07-14 CZ CZ200240A patent/CZ200240A3/cs unknown
- 2000-07-14 AT AT00943706T patent/ATE411041T1/de not_active IP Right Cessation
- 2000-07-14 PL PL00353035A patent/PL353035A1/xx not_active Application Discontinuation
- 2000-07-14 BR BR0012408-7A patent/BR0012408A/pt not_active Application Discontinuation
- 2000-07-14 JP JP2001510411A patent/JP2003525028A/ja active Pending
- 2000-07-14 CN CNB008102287A patent/CN100411684C/zh not_active Expired - Fee Related
- 2000-07-14 MX MXPA02000468A patent/MXPA02000468A/es not_active Application Discontinuation
- 2000-07-14 WO PCT/DK2000/000401 patent/WO2001005353A2/en not_active Ceased
- 2000-07-14 CA CA002378249A patent/CA2378249A1/en not_active Abandoned
- 2000-07-14 HU HU0302052A patent/HUP0302052A3/hu unknown
- 2000-07-14 ES ES00943706T patent/ES2316372T3/es not_active Expired - Lifetime
-
2002
- 2002-01-11 NO NO20020130A patent/NO20020130L/no unknown
- 2002-01-14 US US10/051,044 patent/US20020193302A1/en not_active Abandoned
-
2005
- 2005-06-14 US US11/152,468 patent/US20050239708A1/en not_active Abandoned
-
2008
- 2008-07-23 US US12/178,126 patent/US7829529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100411684C (zh) | 2008-08-20 |
| EP1200116B1 (de) | 2008-10-15 |
| JP2003525028A (ja) | 2003-08-26 |
| WO2001005353A2 (en) | 2001-01-25 |
| KR100821644B1 (ko) | 2008-04-11 |
| PL353035A1 (en) | 2003-10-06 |
| AU5807500A (en) | 2001-02-05 |
| ES2316372T3 (es) | 2009-04-16 |
| NO20020130D0 (no) | 2002-01-11 |
| MXPA02000468A (es) | 2008-10-06 |
| EP1200116A2 (de) | 2002-05-02 |
| BR0012408A (pt) | 2002-03-12 |
| US20020193302A1 (en) | 2002-12-19 |
| DE60040539D1 (de) | 2008-11-27 |
| RU2268744C2 (ru) | 2006-01-27 |
| WO2001005353A3 (en) | 2001-07-19 |
| HUP0302052A3 (en) | 2005-12-28 |
| CA2378249A1 (en) | 2001-01-25 |
| US7829529B2 (en) | 2010-11-09 |
| US20050239708A1 (en) | 2005-10-27 |
| US20090036378A1 (en) | 2009-02-05 |
| CZ200240A3 (cs) | 2003-04-16 |
| NO20020130L (no) | 2002-03-13 |
| KR20020025194A (ko) | 2002-04-03 |
| HUP0302052A2 (hu) | 2003-09-29 |
| CN1460024A (zh) | 2003-12-03 |
| IL147294A0 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60040539D1 (de) | VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS | |
| ATE418336T1 (de) | Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie | |
| ATE414556T1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
| ATE299369T1 (de) | Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| WO2005112981A3 (en) | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells | |
| ATE452642T1 (de) | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen | |
| ATE275919T1 (de) | Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen | |
| MX2009004051A (es) | Uso de antagonistas de il-1 para tratar gota y pseudo gota. | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| ATE217514T1 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
| ATE271873T1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| ATE454155T1 (de) | Verwendung von drospirenon zur behandlung von hypertension | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| ATE222101T1 (de) | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden | |
| DE69825187D1 (de) | Metallische Prothese zur Unterstützung und/ oder zum Ersatz von offenzelligem Gewebe | |
| BR0315344A (pt) | Métodos para prever edema como um efeito colateral do tratamento com drogas | |
| ATE362923T1 (de) | 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| ATE333452T1 (de) | 4-(penylpiperidin-4-ylidenmethyl)benzamidderiva e und deren verwendung zur behandlung von schmerzen,angstzuständen oder erkrankungen des magen-darm- trakts | |
| DE50313329D1 (de) | 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| ATE257384T1 (de) | Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen | |
| ATE465728T1 (de) | Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen | |
| DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |